Skip to main content

Table 1 Patient characteristics by OAT and intracranial bleeding location

From: Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry

  VKA-ICH
n = 32
DOAC-ICH
n = 25
p-value VKA-SDH
n = 23
DOAC-SDH
n = 14
p-value
Male sex 18 (56.2%) 12 (48.0%) p = 0.5994 16 (69.6%) 11 (78.6%) p = 0.7099
Age 76.0 ± 13.4 78.5 ± 8.4 p = 0.5194 76.6 ± 10.4 82.1 ± 6.4 p = 0.1578
Age > 65 y 28 (87.5%) 23 (92.0%) p = 0.6856 19 (82.6%) 14 (100%) p = 0.2760
Height [m] 1.7 ± 0.1 1.7 ± 0.1 p = 0.3717 1.7 ± 0.1 1.7 ± 0.1 p = 0.8189
Weight [kg] 84.4 ± 16.0 76.9 ± 15.3 p = 0.0544 82.0 ± 25.6 83.4 ± 10.5 p = 0.3979
BMI [kg/m2] 28.1 ± 5.5 26.3 ± 5.1 p = 0.0619 26.7 ± 6.9 27.6 ± 5.2 p = 0.5700
Antiplatelet drugs 2 (6.2%) 2 (8.0%) p = 1.0000 7 (30.4%) 4 (28.6%) p = 1.0000
Indication       
 Non-valvular arterial fibrillation 22 (68.8%) 20 (87.0%) p = 0.3805 19 (82.6%) 11 (78.6%) p = 1.000
 Deep vein thrombosis 3 (9.4%) 0 (0.0%) p = 0.2481 1 (4.3%) 1 (7.1%) p = 1.0000
 Other or unknown 7 (21.9%) 5 (20,0%) p = 1.0000 3 (13.0%) 2 (14.3%) p = 1.000
CHADS-VASC Score 4.7 ± 1.7 4.3 ± 1.6 p = 0.4736 4.9 ± 2.0 4.4 ± 1.1 p = 0.2893
HAS-BLED Score 2.8 ± 0.8 2.6 ± 1.1 p = 0.6929 2.5 ± 1.3 2.8 ± 1.0 p = 0.7086
HAS-BLED Score modified 2.7 ± 0.9 2.5 ± 1.0 p = 0.6616 2.4 ± 1.1 2.8 ± 1.0 p = 0.4513
Treatment       
 Apixaban   10 (40%)    8 (57.1%)  
 Edoxaban      1 (7.1%)  
 Rivaroxaban   15 (60%)    5 (35.7%)  
 Phenprocoumon 32    23   
  1. Data are presented as n (%) or mean ± SD